Rationale: As a programmed cell death 1 (PD-1) inhibitor, camrelizumab is used in the treatment of a variety of malignancies. However, a variety of immune-mediated adverse reactions have been reported in a wide range of clinical applications, including immune-related colitis, arthritis, hepatitis, etc.
Patient Concerns: This 56-year-old male patient experienced diarrhea, bloody stool, and knee pain after receiving camrelizumab for metastatic esophageal squamous cell carcinoma. Colonoscopy showed granular changes in the whole colonic mucosa and blurred or even disappeared vascular texture. Pathology showed chronic inflammation of the colonic mucosa. Magnetic resonance imaging of knee joint showed exudative inflammatory changes in bilateral knee joints.
Diagnosis: Immune checkpoint inhibitor-induced colitis and arthritis.
Interventions: Mesalazine oral (extended-release granules, 1000 mg/quarter in die daily). Dexamethasone sodium phosphate (once daily, 5mg in the evening) and compound cypress liquid (once daily, 100ml in the evening) were given by enema. Anti-inflammatory and analgesic treatment of bone pain plaster.
Outcomes: The patient had diarrhea reduced to 3 times/day, no more bloody stools, and the knee pain was relieved.
Lessons: This article describes the cases of immune-related colitis and arthritis caused by camrelizumab, and recommends considering the risk of colitis and arthritis with camrelizumab monotherapy or combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713166 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000036334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.
Muscle Nerve
January 2025
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Introduction/aims: Tofacitinib, a first-generation Janus kinase (JAK) 1/3 inhibitor, is commonly used for treating ulcerative colitis and rheumatoid arthritis. However, its role in myasthenia gravis (MG) remains unclear. This study aimed to evaluate the immunomodulatory effects of tofacitinib on experimental autoimmune myasthenia gravis (EAMG) and peripheral blood mononuclear cells (PBMCs) from patients with MG.
View Article and Find Full Text PDFAdvancing allergic rhinitis research through phenome-wide association studies: Insights from known genetic loci.
World Allergy Organ J
January 2025
Institute of Life Science, Chongqing Medical University, Chongqing, China.
Background: Allergic rhinitis (AR) is a common chronic respiratory disease that can lead to the development of various other conditions. Although genetic risk loci associated with AR have been reported, the connections between these loci and AR comorbidities or other diseases remain unclear.
Methods: This study conducted a phenome-wide association study (PheWAS) using known AR risk loci to explore the impact of known AR risk variants on a broad spectrum of phenotypes.
Deconditioning in quiescent Crohn's Disease patients with heightened fatigue perception.
J Crohns Colitis
January 2025
Professor of Gastroenterology, Translational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
Background & Objective: IBD fatigue aetiology is poorly understood. This study quantified body composition and physical function alongside proton magnetic resonance imaging (1H MRI) and spectroscopy (31P MRS) measures of organ structure and function in quiescent Crohn's Disease patients (CD) and healthy volunteers (HV), to identify a physiological basis for IBD fatigue.
Methods: Body composition was determined using DEXA and 1H MRI.
Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis.
Immun Inflamm Dis
January 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria, Negrar, Italy.
Background: Immune-mediated inflammatory diseases (IMIDs) are a group of chronic conditions characterized by dysregulated immune responses and persistent inflammation. Rheumatoid arthritis (RA), spondyloarthritis (SpA), and ulcerative colitis (UC) exemplify prominent IMIDs, each presenting unique challenges for their management, that impact patient's quality of life (QoL). Obesity, marked by persistent low-grade inflammation, influences the progression, response to treatment, and clinical management of patients with RA, SpA, and UC.
View Article and Find Full Text PDFPrevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients with Inflammatory Bowel Disease.
Am J Gastroenterol
January 2025
University of Chicago Medicine, Inflammatory Bowel Disease Center.
Article Synopsis
- Spondyloarthritis (SpA) is a common condition among patients with inflammatory bowel disease (IBD), affecting up to 39% of individuals but lacks well-defined risk factors.
- The study involved assessing 588 IBD patients using two validated questionnaires to identify SpA symptoms, revealing significant positive screenings for SpA among these patients.
- Key risk factors for positive SpA screens included being female, older age, a history of smoking, bowel surgery, and exposure to biologic treatments, with a concerning number of undiagnosed cases identified.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!